Altimmune Ph2 Obesity and Ph1b T2DM Pemvidutide Data

Altimmune announced topline results from a Week 24 interim analysis of pemvidutide (QW GLP-1/GCG dual agonist) in its 48-week MOMENTUM Ph2 obesity trial (view CT.gov record) along with full results from the 12-week Ph1b safety trial in subjects with obesity or overweight and T2DM (view CT.gov record). The company hosted an associated investor call to discuss the results (webcast; slides). Of note, Altimmune stated it is on track to initiate a Ph3 obesity trial in H1 2023. Following the news, Altimmune’s stock price decreased approximately -54%. Below, FENIX provides highlights and insights, including thoughts on whether Altimmune will be able to differentiate pemvidutide from semaglutide, tirzepatide, and other dual agonists in development.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.